Welcome to our dedicated page for Avadel Pharmaceu SEC filings (Ticker: AVDL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial tables, FDA letters, and royalty footnotes buried in Avadel Pharmaceuticals’ SEC forms can overwhelm even seasoned analysts. When the once-at-bedtime LUMRYZ story spans hundreds of pages, pinpointing safety data or patent-expiry timelines becomes a serious time drain.
Stock Titan solves that problem. Our AI parses every Avadel Pharmaceuticals quarterly earnings report 10-Q filing and annual report 10-K, flags key metrics, and delivers concise explanations. Want Avadel Pharmaceuticals insider trading Form 4 transactions? You’ll get real-time alerts the moment they hit EDGAR. Need Avadel Pharmaceuticals proxy statement executive compensation details or the latest 8-K material events explained? We surface them in plain language, linking disclosures to clinical and commercial milestones.
Here’s how professionals use the page:
- Monitor Avadel Pharmaceuticals Form 4 insider transactions real-time to gauge executive confidence ahead of FDA decisions.
- Compare cash burn and R&D trends with our Avadel Pharmaceuticals earnings report filing analysis, updated the instant a document posts.
- Save hours understanding Avadel Pharmaceuticals SEC documents with AI; complex note references are distilled into clear, actionable summaries.
Janus Henderson Group plc reports beneficial ownership stakes in Avadel Pharmaceuticals plc common stock on a Schedule 13G/A filing. The filing names Janus Henderson as the reporting person and lists aggregate holdings of approximately 11.13 million shares (shown as 11,132,131 in one section and 11,080,442 in Item 4), representing about 11.5%–11.4% of the class. The filing identifies indirect subsidiaries JHIUS, JHIUKL and JHIAIFML as involved in investment-advisory activities and states the position is held in the ordinary course of business and not to influence control. The statement is signed by Janus Henderson compliance on 08/14/2025 and references the issuer address in Dublin.
Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi filed a Schedule 13G/A reporting that Two Seas Global (Master) Fund LP holds 6,155,074 ordinary shares of Avadel Pharmaceuticals plc (CUSIP G29687103), representing 6.4% of the class as of June 30, 2025. The filing states that Two Seas Capital LP, as investment adviser to the Global Fund, and Two Seas Capital GP LLC, as its general partner, each may be deemed to have sole voting and dispositive power over these shares, and that Sina Toussi may be deemed to have those powers through his roles with the adviser and GP. The principal business office for the reporting persons is listed as 32 Elm Place, 3rd Floor, Rye, New York 10580. The filing references 96,777,000 shares outstanding used to calculate the 6.4% stake and is signed by Sina Toussi on 08/13/2025. The report covers the event date 06/30/2025.
FAQ
What is the current stock price of Avadel Pharmaceu (AVDL)?
What is the market cap of Avadel Pharmaceu (AVDL)?
